Intercell and Merck expand alliance to develop prophylactic vaccine and antibody treatments against Group A Streptococcus
The agreement is based on antigens that were discovered and validated by Intercell's proprietary bacterial Antigen Identification Program (AIP®). The agreement also includes an option for Merck to develop human monoclonal antibodies directed against antigens identified by Intercell to treat and protect against severe infections caused by Group A Streptococcus.
Under the terms of the agreement, Intercell will provide to Merck certain Group A Streptococcusspecific antigens identified by its Antigen Identification Program (AIP®) that have promising profiles in preclinical vaccine models. Intercell will receive an upfront payment of USD 9.5 million and is eligible to receive milestone payments up to USD 76 million over the term of the agreement. Intercell will also receive royalties on future net sales of the product.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous